Asqual Getaneh

asqual-getanehAsqual Getaneh, MD, is an attending physician in Internal Medicine at MedStar Washington Hospital Center and a research physician for MedStar Health Research Institute. She specializes in diabetes and obesity.

Her work, on topics ranging from the prevalence of diabetes, obesity and hypertension; diabetes control in Hispanics; and weight loss attempts among new immigrants, has been published in peer-reviewed journals, such as the Journal of General Internal Medicine and the Journal of Immigrant and Minority Health. Dr. Getaneh also has been engaged in research on outcomes of hypertension management and has contributed to work on the use of electronic health records in clinical research. She is a member of the American College of Physicians, the American Diabetes Association, the National Medical Association and the Society of General Internal Medicine. Dr. Getaneh is board certified in Internal Medicine.

Her medical degree is from the University of Washington School of Medicine, Seattle. In addition, she has a Master’s of Public Health degree from the University of Washington School of Public Health and Community Medicine, Seattle, WA. She completed an internship in Internal Medicine at Albert Einstein College of Medicine, New York City, where she also completed a residency in Primary Care/Internal Medicine. While in New York, she studied Nutrition at the Institute of Human Nutrition at Columbia University College of Physicians and Surgeons.

Research Interests

Dr. Getaneh’s research interests include

  • Internal medicine
  • Diabetes
  • Diabetes management
  • Diabetes medications
  • Hypertension
  • Obesity/nutrition
  • Risk factors
  • Cardiovascular disease
  • Health services research

Selected Research

Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)

Dr. Getaneh is an investigator on this randomized placebo-controlled study of treatment regimens for patients with type 2 diabetes. Sponsored by Merck, this study will determine the impact of including sitagliptin as part of usual care vs. usual care without sitagliptin on cardiovascular outcomes as measured by cardiovascular-related death, nonfatal myocardial infarction, nonfatal stroke or unstable angina requiring hospitalization.

Action to Control Cardiovascular Risk in Diabetes (ACCORD)

Dr. Getaneh is a co-investigator on this study sponsored by the National Heart, Lung and Blood Institute. This study is designed to prevent major cardiovascular events (heart attack, stroke, or cardiovascular death) in adults with type 2 diabetes through the use of intensive glycemic control, blood pressure control, and lipid management.

View Dr. Getaneh's publications on PubMed

  • Research Areas
  • Endocrine/Diabetes/Lipids
  • Health Services/Quality/Outcomes